streetinsider

TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook

DelveInsight’s, “Transforming Growth Factor Beta Inhibitors Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Transforming Growth Factor Beta ...
Drug Target Review

KRAS inhibition and CTLA-4 blockade could overcome gastric cancer immunotherapy resistance

A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...
ascopubs.org

A phase II double window of opportunity trial evaluating the oral TGF-beta receptor I inhibitor vactosertib in patients undergoing standard of care preoperative therapy for ...

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal ...
Medical Xpress

Study finds TGF-beta and RAS signaling are both required for lung cancer metastasis

When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...
EurekAlert!

TGF-beta and RAS signaling are both required for lung cancer metastasis, study finds

When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...